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1. Introduction
  Intraocular pressure of glaucoma patients stays 
intermittent or continuous high, and continuous high 
intraocular pressure can cause damage of eyeball tissue or 
visual function to finally cause  vision loss even blindness 
with modality of less than 1%, however, it has become one 
of three blinding diseases universally[1,2]. Most researches 
consider that damage of retinal ganglion cells (RGCs) is the 
main reason for blindness of glaucoma patients, but recently 
there is no effective method to prevent progressive apoptosis 
of RGCs[3,4]. Thus, in recent years researchers start to apply 
retinal stem cells transplantation to treat this disease[5]. 
This study aims to analyze effects of RSCs combined with 
copolymer-1 (COP-1) on glaucoma rat model.
2. Materials and methods
2.1. Experiment materials
  A total of 50 SD clean grade rats aged 8-10 weeks and 
weighted 180-220 g which were purchased from Institute of 
Laboratory Animal, Chinese Academy of Medical Sciences 
were selected. Animal qualified number was 01-3001. 
The rats were kept in clean animal house of experimental 
animal institute (Certification NO: SYXK11-00-0014) under 
environment temperature 20-23 ℃ and humidity 40%-80%. 
Male and female were separated and fed with water and 
food freely.
2.2. Establishment of glaucoma model
  A total of 532 laser diodes were used to photocoagulate 
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corneal limbus vascular network, temporal corneal limbus, 
superior temporal sclera superficial vein and inferior 
temporal sclera superficial vein of 40 rats. The rest 10 rats 
were not given any special treatment. Intraocular pressure, 
conjunctiva, cornea and aqueous water of rats were observed 
21 days after photocoagulation[6,7].
2.3. Retina stem cell culture 
  Five SD rats from control group were selected and 
removed eye balls under general anesthesia, and other 
tissue of eyeball was removed under microscope only with 
marginal part of ciliary body tissue kept. The tissue was 
cut into pieces and digested by 0.25% trypsin plus 0.02% 
EDTA solution. After 7 minutes medium with 10% FBS was 
used to stop digestion and the sample was centrifuged 
for two times by 1 000 r/min. The cells were added with 
medium and inoculated in culture bottles after discarding 
supernatant. The cells were cultured under 37 ℃ and 5% 
CO2. Immunofluorescent staining was used to identify RSCs 
and primary cells were kept for experiment[8,9].
2.4. Treatment of different groups
  A total of 40 glaucoma model rats were numbered and 
randomly divided into A, B, C and D groups. Phosphate 
buffer solution (PBS) were injected in group A and C, COP-1 
were injected in group B and D on d1. PBS were injected in 
group A and B, COP-1 were injected in group C and D on d7.
2.5. Indexes observation
  Expression of brain-derived neurotrophic factor (BDNF) 
and insulin like growth factor-1 (IGF-1) was tested in groups 
2-3 weeks after treatment by immunofluorescent assay. 
Polymerase chain reaction (PCR) was used to compare the 
mRNA expression difference[10]. Western blot was used 
to compare expression of BNDF and IGF-1[11]. Terminal-
deoxynucleoitidyl transferase mediated nick end labeling 
was used to observe RGCs apoptosis of rat retina tissue 
frozen section[12,13].
2.6. Statistical analysis
  All data in our study were analyzed by SPSS13.0. 
Enumeration data was analyzed by Chi-square test and 
measurement data was analyzed by t test. The test level was 
set as 毩=0.05. The difference was considered as statistically 
significant when P＜0.05.
3. Results
3.1. Immunofluorescent staining results
  BDNF and IGF-1 showed positive expression with red color 
in B, C and D groups and mainly concentrated at nerve fiber 
layer and retinal ganglion cell layer, as shown in Figure 1.
BDNF                                                                   IGF-1
 
Figure 1. Expression of BDNF and IGF-1 under confocal microscope 
in group D.
3.2. mRNA expression difference 
  Expression of BDNF and IGF-1 was significantly higher in 
group D compared with the other three groups. Expression 
of BDNF and IGF-1 in group A was significantly lower than 
the other three groups (P＜0.05), there was no significant 
difference between group B and group C (P＞0.05), as shown 
in Table 1.
Table 1
BDNF and IGF-1 mRNA expression (x依sd).
Group Number of cases BDNF IGF-1
A 10 1.23依0.12b 1.00依0.04b
B 10 2.24依0.37ab 1.72依0.16ab
C 10 1.97依0.23ab 1.44依0.57ab
D 10 3.37依0.45a 2.21依0.20a
Note: a Compared with group A, P＜0.05; b Compared with group D, P
＜0.05.
3.3. Protein expression 
  Western blot analysis showed that BDNF and IGF-1 protein 
expression in group D was significantly higher compared 
with the other 3 groups, BDNF and IGF-1 protein expression 
in group A was significantly lower compared with the other 
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three groups (P＜0.05), there was no statistical difference 





Figure 2. Protein expression of BDNF and IGF-1.
Table 2
Protein expression of BDNF and IGF-1 in 4 groups (x依sd).
Group Number of cases BDNF grey value IGF-1 grey value
A 10 0.74依0.07b 0.55依0.09b
B 10 1.35依0.09ab 0.86依0.15ab
C 10 0.83依0.25ab 0.68依0.10ab
D 10 1.60依0.13a 0.98依0.11a
Note: a Compared with group A, P＜0.05; b Compared with group A, 
P＜0.05.
3.4. Analysis of RGCs apoptosis
  The average value of apoptosis cells in single vision was 
11.2 in group A, 9.0 in group B, 9.5 in group C and 6.2 in 
group D. The amount of apoptotic RGCs was significantly 
lower in group D than the other 3 groups, The amount of 
apoptotic RGCs was significantly higher in group A than 
the other 3 groups (P＜0.05), the amount had no statistical 
difference between group B and group C (P＞0.05).
4. Discussion
  In recent years, scholars have been looking for better 
methods to treat glaucoma from optimal nerve regeneration, 
RSCs transplantation and induction of RSCs directional 
differentiation. Stem cells are potential in self-renewal 
and differentiation. Researchers have verified that nerve 
stem cells can merge into rat tissue to promote formation of 
mature brain cells[10,11]. However there is less research about 
RSCs merging in rat retina. Besides, Niyadurupola et al[12-15] 
found that immune system showed significant effects on the 
development of glaucoma, and artificial COP-1 can protect 
the immune reaction to stop secondary damage of RGCs. To 
explore RSCs transplantation combined with COP-1 immune 
therapy on treating glaucoma we selected 50 SD rats for 
research.
  Researchers have found that BDNF and IGF-1 showed 
positive expression in rat retina after RSCs transplantation or 
COP-1 immunotherapy, however, positive expression rate, 
mRNA and protein  expression of BDNF and IGF-1 in rats 
which accepted RSCs transplantation combined with COP-1 
immunotherapy was significantly higher than the other 3 
groups, amount of apoptotic RGCs was also lowest, showing 
that nerve nutrition and growth factor recovered effectively 
in this group to promote the calcium ion concentration, 
decrease partial pressure of oxygen, and inhibit free oxygen 
radicals and release of harmful neurotransmitter to further 
stop RGCs apoptosis and decrease intraocular pressure[16-20], 
the mechanism is as follows: BDNF can be active in rats for 
a long term and release nutrition factor to supply nutrition 
and protection for glaucoma rats; As a self-reactive antigen, 
injection of COP-1 can activate local immune reaction 
and microglial cells to remove pieces of dead cells and 
glutamic acid. Besides, Werkmeister et al[21-30] found that 
RSCs transplantation combined with COP-1 could provide 
protection for central nerve cells and promote production of 
IGF-1, it’s also critical in regulation of nerve formation.
  In conclusion, RSCs transplantation combined with COP-1 
immunotherapy can promote the secretion of BDNF and 
IGF-1, collaboratively protect RGCs in glaucoma rats, which 
significantly reduces the number of apoptosis RGCs so as 
to alleviate the optic nerve damage to open a new research 
direction for treatment of glaucoma.
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